Eli Lilly reveals two-year data for experimental eczema treatment after FDA roadblock

Eli Lil­ly is bol­ster­ing the case for its ex­per­i­men­tal eczema treat­ment le­brik­izum­ab with a first look at how pa­tients fared af­ter two years of main­te­nance treat­ment.

Al­most 80% of mod­er­ate-to-se­vere atopic der­mati­tis pa­tients on once-month­ly le­brik­izum­ab main­tained clear or al­most clear skin at two years, Lil­ly an­nounced on Fri­day. The safe­ty pro­file was al­so “con­sis­tent with pre­vi­ous le­brik­izum­ab stud­ies in pa­tients with mod­er­ate-to-se­vere atopic der­mati­tis” with no new sig­nals seen, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.